DC-806
- Generic Name
- DC-806
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 104
- Registration Number
- NCT06808815
- Locations
- 🇬🇧
The Medicines Evaluation Unit (MEU) Ltd., Manchester, United Kingdom
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT06092931
- Locations
- 🇺🇸
ICON Phase 1 Clinic, Salt Lake City, Utah, United States
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT06045000
- Locations
- 🇳🇱
ICON Phase 1 Clinic, Groningen, Netherlands
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT05994807
- Locations
- 🇺🇸
ICON Phase I Clinic, Salt Lake City, Utah, United States
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 229
- Registration Number
- NCT05896527
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇨🇦Lynderm Research Inc. - Probity - PPDS, Markham, Ontario, Canada
ðŸ‡ðŸ‡ºMedMare Bt, Veszprém, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath